Oncolytics Biotech Reports 2018 Third Quarter Financial Results and Provides Corporate Update


Oncolytics BiotechA Inc. , currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced financial results and operational highlights for the quarter ended September 30, 2018. All dollar amounts are Canadian unless otherwise noted.



from Biotech News